Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.
You may also be interested in...
Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.
FDA Approves Simponi For Ulcerative Colitis
J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.
Inflammatory Bowel Drugs To Go Head-To-Head With PCORI Funding
A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.